Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abpro Holdings Inc. stock logo
ABP
Abpro
$0.25
+0.6%
$0.24
$0.15
$13.00
$19.65M0.036.14 million shs3.32 million shs
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
$0.84
-1.4%
$0.75
$0.49
$2.59
$75.35M1.89172,341 shs82,615 shs
CEL-SCI Co. stock logo
CVM
CEL-SCI
$10.43
+12.0%
$6.28
$1.98
$39.30
$71.78M0.52373,970 shs514,864 shs
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$1.27
$1.28
$0.92
$22.50
$76.57M0.6480,746 shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abpro Holdings Inc. stock logo
ABP
Abpro
0.00%-1.57%-5.15%+13.26%+24,509,900.00%
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
0.00%-5.94%+15.07%+43.34%-65.85%
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.00%+9.56%+27.51%+396.67%-67.96%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
0.00%0.00%0.00%-0.78%-87.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abpro Holdings Inc. stock logo
ABP
Abpro
N/AN/AN/AN/AN/AN/AN/AN/A
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
3.5171 of 5 stars
3.64.00.00.03.31.71.3
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.4868 of 5 stars
0.04.00.00.00.01.70.6
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
4.5431 of 5 stars
3.03.00.04.63.83.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abpro Holdings Inc. stock logo
ABP
Abpro
3.00
Buy$4.001,531.99% Upside
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
3.17
Buy$5.25525.00% Upside
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.00
N/AN/AN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
1.90
Reduce$5.50333.07% Upside

Current Analyst Ratings Breakdown

Latest ABP, CNTX, CVM, and IGMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/7/2025
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $4.00
8/7/2025
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/26/2025
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$4.50 ➝ $4.00
(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abpro Holdings Inc. stock logo
ABP
Abpro
$180K109.16N/AN/A($0.21) per share-1.17
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
N/AN/AN/AN/A$0.92 per shareN/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/A$0.15 per shareN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$145.05M0.53N/AN/A$1.67 per share0.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abpro Holdings Inc. stock logo
ABP
Abpro
-$7.23MN/A0.00N/AN/AN/A-241.16%N/A
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
-$26.73M-$0.36N/AN/AN/AN/A-38.80%-37.53%11/5/2025 (Estimated)
CEL-SCI Co. stock logo
CVM
CEL-SCI
-$26.92M-$9.77N/AN/AN/AN/A-238.05%-104.65%N/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$195.79M-$0.90N/AN/AN/A-36.81%-93.35%-24.15%11/14/2025 (Estimated)

Latest ABP, CNTX, CVM, and IGMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Abpro Holdings Inc. stock logo
ABP
Abpro
N/A-$0.04N/A-$0.05N/AN/A
8/6/2025Q2 2025
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
-$0.06-$0.09-$0.03-$0.09N/AN/A
7/31/2025Q2 2025
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.30$1.58+$1.88$1.58$3.20 million$143.62 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abpro Holdings Inc. stock logo
ABP
Abpro
N/AN/AN/AN/AN/A
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
N/AN/AN/AN/AN/A
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/AN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abpro Holdings Inc. stock logo
ABP
Abpro
N/A
0.15
0.15
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
N/A
19.09
19.09
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.66
1.07
1.09
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/A
17.66
17.66

Institutional Ownership

CompanyInstitutional Ownership
Abpro Holdings Inc. stock logo
ABP
Abpro
23.30%
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
14.03%
CEL-SCI Co. stock logo
CVM
CEL-SCI
12.08%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
42.79%

Insider Ownership

CompanyInsider Ownership
Abpro Holdings Inc. stock logo
ABP
Abpro
20.80%
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
2.80%
CEL-SCI Co. stock logo
CVM
CEL-SCI
9.93%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
57.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abpro Holdings Inc. stock logo
ABP
Abpro
1580.17 million63.49 millionN/A
Context Therapeutics Inc. stock logo
CNTX
Context Therapeutics
789.70 million87.19 millionNot Optionable
CEL-SCI Co. stock logo
CVM
CEL-SCI
436.88 million64.67 millionOptionable
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
19060.29 million25.93 millionOptionable

Recent News About These Companies

IGM Biosciences to be acquired by Concentra
IGM Biosciences ends agreement with Sanofi

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abpro stock logo

Abpro NASDAQ:ABP

$0.25 +0.00 (+0.57%)
As of 08/29/2025 03:59 PM Eastern

Abpro Holdings Inc. is a biotechnology company. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.

Context Therapeutics stock logo

Context Therapeutics NASDAQ:CNTX

$0.84 -0.01 (-1.20%)
As of 08/29/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

CEL-SCI stock logo

CEL-SCI NYSE:CVM

$10.43 +1.12 (+12.03%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$10.46 +0.03 (+0.25%)
As of 08/29/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

IGM Biosciences stock logo

IGM Biosciences NASDAQ:IGMS

$1.27 0.00 (0.00%)
As of 08/14/2025

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.